OrbiMed, the global investment firm focused on the healthcare sector, has closed its latest venture capital fund, at $950m.
Limited partners include some medical research institutions globally, along with endowments, foundations and sovereign wealth funds.
Consistent with its predecessor funds, OrbiMed Private Investments VI, LP, will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceuticals, medical devices, diagnostics and healthcare IT companies located in North America and Europe.
Led by Carl Gordon and Jonathan Silverstein, the new fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $75 million.
With over $16 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital startups to large multinational companies utilizing a range of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. The firm, which has headquarters in New York City, and additional offices in San Francisco, Shanghai, Mumbai and Herzliya, Israel, has just launched a $300m healthcare venture capital fund focused on Israel.